“Amicable Agreement”
This article was originally published in The Gray Sheet
Executive Summary
Regardless of any positives or negatives associated with the protracted CEO transition at Boston Scientific, one primary driver for the arrangement appears to be an agreement hashed out between the company and Johnson & Johnson allowing Mahoney to make the move in the near term without flouting non-compete requirements for former J&J executives.
You may also be interested in...
Boston Scientific Wins Guidant Takeover Battle, Ending Fierce Bidding War
Boston Scientific faces the monumental task of integrating ICD-manufacturer Guidant following a $27.2 bil. acquisition victory over Johnson & Johnson on Jan. 25
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.